Response to lorlatinib rechallenge in a case of ALK-rearranged metastatic NSCLC with a resistance mutation to second generation TKIs

突变 癌症研究 医学 后天抵抗 抗性(生态学) 肿瘤科 内科学 生物 癌症 遗传学 基因 生态学
作者
Rita Leporati,Daniela Miliziano,Teresa Beninato,Laura Mazzeo,Sara Manglaviti,Marta Brambilla,Mario Occhipinti,Arsela Prelaj,Claudia Proto,Giuseppe Lo Russo
出处
期刊:Tumori Journal [SAGE]
标识
DOI:10.1177/03008916241246659
摘要

Several anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) have been developed for the treatment of echinoderm microtubule-associated protein-like 4 (EML4)-ALK-rearranged non-small cell lung cancer (NSCLC), with the newer generation agents brigatinib, alectinib and lorlatinib showing prolonged responses. With the increasing number of target therapies available, the optimal sequence is yet to be defined, as resistance profiles may evolve over time and in response to sequential ALK inhibitors. Therefore, ALK-targeted strategies may be personalized based upon the presence of specific ALK resistance mutations.Here, we report on the case of a patient who has been treated with a sequence of three ALK TKIs after receiving diagnosis of ALK-rearranged metastatic NSCLC in 2015 and gained further benefit upon lorlatinib rechallenge after the acquisition of the G1202R resistance mutation to second generation TKIs.In this case, the first ALK resistance mutation detected after progression on first line TKI, the I1171N, is a common resistance mutation after alectinib and confers sensitivity to brigatinib, that the patient received afterwards with a long-term disease stability. The second ALK resistance mutation detected after a chemotherapy interval, the G1202R, is the most common resistance mutation after second generation ALK TKIs and has been associated with sensitivity to third generation TKIs, such as lorlatinib. This case of a patient with EML4-ALK-rearranged NSCLC shows that sequential treatment with next-generation ALK TKIs, including rechallenge, can induce profound remissions, even in heavily pretreated patients, and that ALK-targeted strategies may be personalized by considering the presence of distinct ALK resistance mutations.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Phoenix完成签到 ,获得积分10
1秒前
许鑫蓁完成签到,获得积分10
2秒前
syne完成签到,获得积分10
13秒前
闲人不贤完成签到,获得积分10
26秒前
ganzhongxin完成签到,获得积分10
27秒前
32秒前
37秒前
清颜完成签到 ,获得积分10
41秒前
绿袖子完成签到,获得积分10
41秒前
Loooong应助科研通管家采纳,获得10
45秒前
新世界科研虫完成签到,获得积分10
45秒前
何一发布了新的文献求助10
55秒前
ran完成签到 ,获得积分10
55秒前
CodeCraft应助GXSH采纳,获得10
1分钟前
huang’发布了新的文献求助20
1分钟前
1分钟前
GXSH发布了新的文献求助10
1分钟前
科研通AI2S应助huang’采纳,获得10
1分钟前
无为完成签到 ,获得积分10
1分钟前
完美世界应助GXSH采纳,获得10
1分钟前
xiaohong完成签到 ,获得积分0
1分钟前
无花果应助Bonnie采纳,获得10
1分钟前
xxxxam完成签到,获得积分10
1分钟前
1分钟前
Bonnie发布了新的文献求助10
1分钟前
老神在在完成签到,获得积分10
1分钟前
坚强的广山应助勇往直前采纳,获得10
1分钟前
JiangHb完成签到,获得积分10
1分钟前
空白完成签到,获得积分10
1分钟前
fanconi完成签到 ,获得积分10
1分钟前
看文献完成签到,获得积分10
2分钟前
Yufan完成签到 ,获得积分10
2分钟前
扬帆起航完成签到 ,获得积分10
2分钟前
认真绿蝶完成签到 ,获得积分10
2分钟前
欣慰歌曲完成签到 ,获得积分10
2分钟前
2分钟前
乐天林完成签到 ,获得积分10
2分钟前
哭泣的映寒完成签到 ,获得积分10
2分钟前
轩轩完成签到 ,获得积分10
2分钟前
木木木完成签到,获得积分10
2分钟前
高分求助中
Un calendrier babylonien des travaux, des signes et des mois: Séries iqqur îpuš 1036
Sustainable Land Management: Strategies to Cope with the Marginalisation of Agriculture 1000
Corrosion and Oxygen Control 600
Python Programming for Linguistics and Digital Humanities: Applications for Text-Focused Fields 500
Heterocyclic Stilbene and Bibenzyl Derivatives in Liverworts: Distribution, Structures, Total Synthesis and Biological Activity 500
重庆市新能源汽车产业大数据招商指南(两链两图两池两库两平台两清单两报告) 400
Division and square root. Digit-recurrence algorithms and implementations 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2546226
求助须知:如何正确求助?哪些是违规求助? 2175672
关于积分的说明 5600355
捐赠科研通 1896427
什么是DOI,文献DOI怎么找? 946285
版权声明 565379
科研通“疑难数据库(出版商)”最低求助积分说明 503557